SNY Sanofi Price-to-Projected Revenue Ratio

Public company logo of Sanofi S.A. (SNY)

The forward P/S of Sanofi (SNY) reflects valuation dynamics where 0.80 characterizes this valuation parameter. Growth is driven by the renewal of the R&D pipeline through AI-discovered molecules and mRNA vaccines. Fundamentals rely on dominance in high-margin rare disease therapies. Business efficiency is further enhanced by a diversified network of logistics hubs, which reduces costs for pharmacy deliveries.

Sanofi S.A. - SNY Forward P/S Multiple (period 07/04/2022 - 11/13/2026)

SNY (Sanofi Group): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price Sanofi S.A.|SNY - Analyst Target Range
- market capitalization data:
Market Value Sanofi Group|SNY - Company Buyout Price
- book value of equity indicators:
Book Value per Share Sanofi|SNY - Book Capitalization|Market Value to Book Value Ratio sanofi.com|SNY - Total Business Assets
- company liabilities and liquidity data:
Debt to Equity Sanofi|SNY - Long-Term Liabilities to Capital|Short-Term Debt to Capital Sanofi|SNY - Company Aggregate Indebtedness|Debts to Book Capitalization Sanofi Group|SNY - Long-Term Debt Volume|Company Short-Term Debt Sanofi|Quick Liquidity sanofi.com
- financial results and valuation multiples details:
SNY - Company Profit|Future Profit Sanofi|SNY - Market Cap to Earnings|Future Price to Earnings Sanofi Aventis|SNY - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Sanofi Group|SNY - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Sanofi|SNY - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months sanofi.com|SNY - Earnings per share increase in current year|Net earnings per share growth forecast for next year Sanofi
- total revenue and sales volume data:
SNY - Company Sales|Projected Sales Volume Sanofi S.A.|SNY - P/S Multiple|Forward Price-to-Revenue Multiple Sanofi Group
Fundamental valuation:Sanofi S.A. SNY
Original product of Sanofi Group

Sanofi (SNY) is integrating eco-design principles and production decarbonization, which impacts the long-term value of its assets. The forward P/S reflects the ratio of current market capitalization to projected revenue, signaling either a market discount or systemic business issues. Analyzing the forward P/S based on forecasts helps investors identify the accumulation phase and avoid overpaying for the company during periods of volatility.

Analysis of competing companies

Forward P/S Multiple LLY (Eli Lilly)|Projected Price to Revenue AbbVie Inc|AZN - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Novartis Pharma NVS|MRK: Forward P/S Multiple|novonordisk.com (NVO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Amgen|Market Cap to Projected Revenue PFE (Pfizer Inc)|Price-to-Projected Revenue Ratio BMS (BMY)|GSK - Market Cap to Future Revenue Ratio|Forward P/S Multiple TAK (Takeda Pharmaceutical)|TEVA (tevapharm.com) - Future Price to Revenue|Dr. Reddy's - Forward P/S Multiple|Market Cap to Expected Sales Ratio Viatris Inc VTRS|Roivant Sciences Ltd (ROIV) - Price-to-Projected Revenue Ratio|ZLAB - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Bausch Health Companies|Market Cap to Projected Revenue COSM (cosmosholdingsinc.com)